Source: Rebel News

An email from Prime Minister Trudeau’s director of policy and cabinet affairs, Rick Theis, to Trudeau’s lead speechwriter, Astrid Krizus, about the ordering of pandemic supplies shows that the writer was suggested to make no mention of the Government of Canada’s purchase of hydroxychloroquine alongside other supplies, when preparing an official statement.

“Below… is the note PCO send [sic] to me on proposed language on PPE/supply,” Theis begins the email. He then relays two paragraphs of information that would seem to be guidance from the Privy Council Office with regard to how the federal government should word its announcement.

Interestingly, in the suggestions aimed at Krizus from the June 1, 2020 email, the speechwriter is told that it may not be best to focus on certain aspects of the government’s pandemic purchases.

“Some elements, we may not want to announce (e.g., the purchase of Hydroxylchloriquine [sic]),” the email notes.

“Thanks Rick,” Krizus replies.

Shortly after that email was sent, the government’s official position on the controversial usage of the drug was to not use it as a method of treatment for COVID-19.

Hydroxychloroquine became a topic of controversy following former U.S. president Donald Trump’s endorsement of the drug as a means for treating and staving off COVID-19. Having first touted the drug’s viability in April 2020, Trump then went on the record in May stating that he had been taking hydroxychloroquine in an effort to defend against the virus.

In June 2020, a study critical of hydroxychloroquine that was published in medical journal The Lancet was withdrawn. Another study released in July showed the anti-malarial drug “helped COVID-19 patients survive better,” according to a CNN report shared by MSN.

The drug would, yet again, be a topic of controversy in July 2020 following an announcement by a group of doctors, one of whom praised the drug for its ability to help those suffering from COVID-19.

The full email can be read below:

Journal of Medicine Says HCQ + Zinc Reduces COVID Deaths

HCQ Peer-reviewed: Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection

Perronne in the NEJM: ‘Recovery’ trial contested – is this finally a breach in the denial around hydroxychloroquine?

Craig Kelly MP, Dr Vladmir Zelenko and early treatment: ‘You don’t have to fall victim to your government’s tyranny’

Hydroxychloroquine & Covid-19: India and France, a cruel comparison


‘I base my comments on science’: Emeritus professor Robert Clancy defends hydroxychloroquine stance

Share on facebook
Share on twitter
Share on whatsapp
On Trend

Latest Stories

Stark madness to ban ivermectin

Buried in the note is the real reason for making ivermectin inaccessible – the fear that persons taking it ‘may elect not to be vaccinated as part of the national Covid-19 vaccination program’. This is outrageous. When someone is infected with Covid, it is too late to bother with vaccination. They need early treatment. To deny it to coerce them into accepting a vaccine, one of whose side-effects is death, is immoral.

Read More »

Australia’s TGA Bans GPs from Prescribing Ivermectin

Australia’s medicine and therapeutic regulatory, the Therapeutic Good Administration (TGA) recently took the gloves off with Ivermectin, the economical anti-parasitic drug associated with at least 63 completed clinical trials involving SARS-CoV-2, the virus behind COVID-19. Now TGA formally places a national prohibition on off-label prescribing of ivermectin to all general practitioners. A comparable move as to what TGA did with hydroxychloroquine in 2020. Clearly further evidence of tightening encroachment of the critically important doctor-patient treatment relationship allowing consent to medical treatment using off-label medications. Of course, this isn’t occurring in a vacuum—it’s part of an unfolding, integrated and what have the signs of a coordinated and orchestrated government action to stop any and all treatments other than those the government declares acceptable.

Read More »